Not every PMA change earns a full supplement

A PMA holder that treats every post-approval change the same way — draft a full supplement, wait out FDA's standard review clock — is choosing the slowest available option far more often than 21 CFR 814.39 actually requires. The section doesn't set one track for changes to an approved device; it sets several, sorted by how much a given change actually risks affecting safety or effectiveness, and the fastest of them don't call for a supplement at all. Getting the sort wrong runs in both directions: a 30-day notice filed for a change that needed full review invites a rejection and a restart from the beginning of the clock; a full supplement drafted for a change a 30-day notice would have covered spends months a manufacturer didn't have to spend.

814.39(a) sets the threshold before any track gets picked

21 CFR 814.39(a) states the baseline duty plainly: an applicant has to submit a PMA supplement for FDA review and approval before making a change that affects the device's safety or effectiveness, unless the change qualifies for one of the alternate submission types the section itself carves out. That threshold question — does this change affect safety or effectiveness — is the PMA-side counterpart to the 807.81(a)(3) test a cleared device runs against, and it has to be answered honestly before a manufacturer starts picking among the faster tracks. A change that clearly doesn't touch safety or effectiveness at all doesn't need any of what follows; one that does still has to be sorted into the right track, not the most convenient one.

Panel-track and 180-day supplements are both full review, sorted by novelty

A panel-track supplement is for changes substantial enough to warrant the same kind of full review an original PMA gets, including the possibility of referral to an outside advisory panel — a significant change in the device's design or performance, or a new indication for use. A 180-day supplement covers ground one notch narrower: a significant change in components, materials, design, specification, software, color additives, or labeling that doesn't rise to panel-track territory. Both are genuine supplements requiring FDA approval before the change ships; the difference between them is how novel or consequential the change is, not how much paperwork either one takes to prepare.

A real-time supplement trades a written cycle for a live meeting

The real-time supplement is built for a narrower case: a minor change — to the device's design, its software, its sterilization method, or its labeling — where the applicant has requested, and FDA has granted, a meeting or similar forum to jointly review and resolve the supplement's status in that session rather than through the standard written back-and-forth. It isn't a lighter-weight version of a 180-day supplement so much as a different review format entirely, available only when the change itself is modest enough that a single joint session can actually settle it.

30-day notices skip the supplement, and site changes don't qualify for the shortcut

Modifications to manufacturing procedures or methods of manufacture that affect safety or effectiveness can, under 814.39(f), bypass the supplement process entirely through a 30-day notice: the applicant describes the change in detail, summarizes the data supporting it, and states that it was made in accordance with the quality system requirements — and can distribute the changed device 30 days after FDA receives the notice unless FDA objects within that window. A related 135-day supplement track exists in the same section for manufacturing-procedure changes that need a fuller FDA review than a 30-day notice but still don't warrant full panel-track or 180-day treatment. What the 30-day notice route doesn't reach is a change of manufacturing or sterilization site, or a change to the device's own design or performance specifications — those still need a full supplement under 814.39(a)(3), regardless of how routine the site move itself might otherwise seem.

Where this meets the file

None of this touches the separate postapproval conditions an approval order itself can attach — a restriction or a required study still runs on the terms that order states, independent of which supplement track a later design change happens to use. A change-classification worksheet that walks a proposed PMA change through 814.39's own tracks in order, before a submission type gets chosen by habit, is previewed in the launch catalog. If your program sorts these differently, the shelf takes that correction directly.